Motzer, R. J., McDermott, D. F., Escudier, B., Burotto, M., Choueiri, T. K., Hammers, H. J., . . . Tannir, N. M. (2022). Conditional survival and long‐term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma. Cancer, 128(11), 2085-2097. https://doi.org/10.1002/cncr.34180
Citácia podle Chicago (17th ed.)Motzer, Robert J., et al. "Conditional Survival and Long‐term Efficacy with Nivolumab Plus Ipilimumab Versus Sunitinib in Patients with Advanced Renal Cell Carcinoma." Cancer 128, no. 11 (2022): 2085-2097. https://doi.org/10.1002/cncr.34180.
Citácia podľa MLA (8th ed.)Motzer, Robert J., et al. "Conditional Survival and Long‐term Efficacy with Nivolumab Plus Ipilimumab Versus Sunitinib in Patients with Advanced Renal Cell Carcinoma." Cancer, vol. 128, no. 11, 2022, pp. 2085-2097, https://doi.org/10.1002/cncr.34180.